Tech Company Financing Transactions
OncoResponse Funding Round
OncoResponse, operating out of Seattle, secured $19.5 million from Baxalta Ventures and private investors.
Transaction Overview
Company Name
Announced On
5/26/2016
Transaction Type
Venture Equity
Amount
$19,499,000
Round
Undisclosed
Investors
Baxalta Ventures (Geeta Vemuri)
Proceeds Purpose
The investment by Baxalta brings the total Series A to $12.5 million and will be used to support OncoResponse's ongoing efforts to interrogate the humoral response of elite responders to cancer immunotherapy to identify antibodies and potential targets for novel therapeutic development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1124 Columbia St. 300
Seattle, WA 98104
USA
Seattle, WA 98104
USA
Phone
Website
Email Address
Overview
OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Clifford Stocks
Chief Medical Officer
Robert Lechleider
Chief Scientific Officer
Kamal Puri
Browse more venture capital transactions:
Prev: 5/26/2016: ExpertDB venture capital transaction
Next: 5/26/2016: Lightbend venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs